Key result
This review discusses the role of monocytes, cytokines, and inflammation in the pathology of chronic heart failure and analyzes drugs used for immune response modulation.
This review highlights the role of inflammation, monocytes, and cytokines in the pathology and decompensation of ischemic chronic heart failure, along with potential immunomodulatory therapies.
Answers are grounded in this paper and cite their sources.
Inflammation modulation in ischemic HF remains investigational; leaves open which agents merit randomized testing.
Recently, a significance has been established, for the role of inflammation in the pathology of chronic heart failure (CHF). It is well known that raised level of circulating pro-inflammatory cytokines in ischemic CHF patients correlate with the severity and prognosis of the disease. Monocytes play key role in an inflammatory cascade and are the main source of pro-, as contra-inflammatory cytokines. Disbalance of physiological inflammation in alteration and healing of the myocardium might lead to formation of pathological chronic inflammation. In the article, the role of monocytes discussed, and of inflammation, in CHF and its decompensation. The kinds of cytokines observed with their role in inflammation. Also, the analysis presented, of the drugs used for modulation of immune response in CHF.
No takes yet. Share an insight, caveat, or question.
Kruchinkina et al. (2018) conducted a review in Decompensated chronic heart failure of ischemic origin. Immune response modulation drugs was evaluated. This review discusses the role of monocytes, cytokines, and inflammation in the pathology of chronic heart failure and analyzes drugs used for immune response modulation.
Synapse has enriched 10 related papers. Consider them for comparative context: